Allogene Stock: Speculative Biotech With Potential In Oncology (NASDAQ:ALLO) TOPICS:Fashion Posted By: Advance April 1, 2022 Allogene Therapeutics’ ALLO-316 was given Fast Track Designation in renal cell carcinoma. Click to see why ALLO is a great speculative biotech stock to look into.
